GLPwatch
Once-weekly semaglutide for obesity or overweight: A systematic review and meta-analysis.
Diabetes Obes Metab · 2022
Last updated 2026-05-28| Journal | Diabetes Obes Metab, 2022 |
|---|---|
| Citations | 9 |
| Relative citation ratio | 0.67 |
| NIH percentile | 37 |
| Molecules | semaglutide |
| Conditions studied | Obesity |
Full record and abstract on PubMed 34866313 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.